Versant Venture Management, LLC Long-Term Concentrated

CIK: 0001560009 · Show all filings

Period: Q4 2017 (← Previous) (Next →)

Filing Date: Jan 25, 2018

Total Value ($000): $95,029,118 (100.0% shares, 0.0% debt)

Holdings (7)

— Audentes Therapeutics, Inc. 39.6%

Value ($000) $37,644,219 Shares 1,204,615 Est. Cost $17810.00 Unrealized —

— Achaogen, Inc. 14.5%

Value ($000) $13,759,572 Shares 1,281,152 Est. Cost $13050.00 Unrealized —

OCUL Ocular Therapeutix, Inc. 10.4%

Value ($000) $9,858,459 Shares 2,215,384 Est. Cost $20.09 Unrealized -74.6%

— CymaBay Therapeutics, Inc. 10.2%

Value ($000) $9,647,127 Shares 1,048,601 Est. Cost $9830.00 Unrealized —

— ImmuneDesign Corp. 9.1%

Value ($000) $8,612,019 Shares 2,208,210 Est. Cost $7580.00 Unrealized —

— Second Sight Medical Products, Inc. 9.0%

Value ($000) $8,581,582 Shares 4,492,975 Est. Cost $1210.00 Unrealized —

— Clovis Oncology, Inc. 7.3%

Value ($000) $6,926,140 Shares 101,855 Est. Cost $56000.00 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
—	Audentes Therapeutics, Inc.	1,204,615	$37,644,219	39.6%	$17810.00	—	Common Stock	05070R104
—	Achaogen, Inc.	1,281,152	$13,759,572	14.5%	$13050.00	—	Common Stock	004449104
OCUL	Ocular Therapeutix, Inc.	2,215,384	$9,858,459	10.4%	$20.09	-74.6%	Common Stock	67576A100
—	CymaBay Therapeutics, Inc.	1,048,601	$9,647,127	10.2%	$9830.00	—	Common Stock	23257D103
—	ImmuneDesign Corp.	2,208,210	$8,612,019	9.1%	$7580.00	—	Common Stock	45252L103
—	Second Sight Medical Products, Inc.	4,492,975	$8,581,582	9.0%	$1210.00	—	Common Stock	81362J100
—	Clovis Oncology, Inc.	101,855	$6,926,140	7.3%	$56000.00	—	Common Stock	189464100